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The epidemiology and pathogenesis of CMV infections among pregnant women have been intensely studied over the last three
decades. This paper highlights recent developments that make either universal or limited serologic screening for CMV during
pregnancy potentially attractive. The developments include an understanding of the pathogenesis of CMV infections, a knowledge
of high-risk women, the availability of accurate methods for the serologic diagnosis of a primary CMV infection using either
single or serial blood samples, accurate methods for the diagnosis of fetal infection via amniotic fluid, sensitive fetal and placental
indicators for neonatal outcomes, and the availability of potentially eﬀective interventions.
1. Introduction
The epidemiology and pathogenesis of CMV infections
among the people of the USA and particularly among
pregnant women have been intensely studied over the last
three decades [1, 2]. We know that a primary CMV infection
during pregnancy is a frequent and serious threat to the
fetuses of pregnant women. Each year in the USA, an
estimated 40,000 pregnant women acquire a primary CMV
infection (seroconvert) during pregnancy. Of the 40,000
women who seroconvert approximately 6,000 to 8,000 of
their infants will develop severe and permanent neurologic
damage from this infection [3]. Another less frequent eﬀect
is fetal death or neonatal death which occurs in about 10%
of fetuses or newborns following an intrauterine CMV infec-
tion. Neurologic damage includes impaired development,
mental retardation, and neurosensory hearing deficit.
The rate of susceptibility to CMV during pregnancy is
also well established. Among women of child-bearing age
between 40% and 80% will be susceptible (seronegative) to
CMV at the beginning of pregnancy. The rate of suscepti-
bility at the beginning of pregnancy varies by ethnic or racial
group with highest rates occurring among African-American
and Hispanic populations [2].
In 1999, the Institute of Medicine issued a report on
priorities for new vaccines and gave development of a CMV
vaccine level-one priority [4]. This was based not only on the
frequency of neurologic disease but also on the fact that CMV
is the most common cause of nonhereditary hearing loss
with an estimated 25 percent of all hearing deficit due to a
congenital CMV infection [5]. Further, CMV is a muchmore
common cause of severe neurological damage in infancy
than was bacterial meningitis, congenital rubella, or neonatal
herpes simplex infections [4].
In spite of the detailed knowledge about the epidemiol-
ogy and pathogenesis of CMV infections in pregnant women,
this infection remains largely unknown to the majority of
women in the United States [6]. Few, if any, pregnant women
are routinely screened for CMV infections during pregnancy.
Questions surrounding the appropriateness of serologic
screening for CMV during pregnancy are important because
over 90% of primary maternal CMV infections during
pregnancy are asymptomatic and may remain asymptomatic
in the fetus. Israel and eight European countries (France,
Belgium, Spain, Italy, Germany, Austria, Portugal, and the
Netherlands) routinely screen the majority of pregnant
women serologically for CMV [7, 8]. This routine serologic
screening occurs without the recommendations or guidelines
of any governmental agency, authority, or a professional
medical society.
Routine serologic screening for CMV of pregnant women
in Europe has yielded very important advances in our
understanding of CMV infections among pregnant women.
Near universal testing in Belgium has yielded definitive
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Figure 1: Relationship of maternal immunity to disease caused by congenital CMV infection. Adapted from [19].
data concerning maternal-fetal transmission rates of CMV
as a function at gestational age [9]. The Italians have
capitalized on national serologic screening to develop and
evaluate methods to diagnose maternal and fetal CMV
infections including the CMV IgG avidity assay, and to test
interventions such as CMV immunoglobulin [10, 11]. The
French have used serologic screening to evaluate the role
of maternal education about CMV and the role of hygienic
intervention to prevent maternal acquisition of CMV during
pregnancy [12].
This paper will highlight recent developments that make
either universal or limited serologic screening for CMV
during pregnancy potentially attractive. The developments
include a much better understanding of the pathogenesis
of CMV infections, a knowledge of high-risk women, the
availability of accurate methods for the serologic diagnosis of
a primary CMV infection using either single or serial blood
samples, accurate methods for the diagnosis of fetal infection
via amniotic fluid, sensitive fetal and placental indicators
for neonatal outcomes, and the availability of potentially
eﬀective interventions.
2. Pathogenesis of Congenital CMV Infections
Figure 1 shows an algorithm which indicates that between
40% and 60% of pregnant women are susceptible to CMV at
conception. Of these, between 1% to 4% will acquire CMV
during pregnancy, and on average between 40% and 50%
of infected women will transmit the virus to the fetus. The
lowest transmission rate (35%) occurs when the maternal
infection is in the first trimester, and as pregnancy progresses,
the transmission rate increases to 73% for women who
acquire CMV infections in the third trimester [9]. Of infants
infected in utero approximately a third will have symptoms or
develop severe neural impairment [11]. This neonatal disease
rate is probably highest for children of women who have
had a primary infection in the first half of pregnancy, but
definitive data on this point are lacking.
There is considerable uncertainty about the role of
maternal immunity to CMV prior to conception. Infants
born of mothers with preconception immunity not only give
birth to infected infants but also occasionally give birth to
infants with symptoms at birth that may develop delayed
sequelae, particularly hearing deficit [3, 13]. Nevertheless,
there is no uncertainty concerning the fact that the rate
of congenital infection among women with preconception
immunity is only between 0.5% and 2% as compared to
an average of 40% to 50% in women who have serocon-
verted during pregnancy. In one study, 3% of prepregnant
women seronegative at or before conception had congenitally
infected infants compared with 1% for women seropositive
before conception [14].
A 1992 study demonstrated the most severe infant
sequelae occurred only among women who had a primary
CMV infection during pregnancy [3]. Infant hearing loss
was observed in women who had a recurring infection, but
it was not nearly as profound as among the children born
of mothers without preconception immunity [13]. Hence,
eliminating or reducing the morbidity associated with a
primary infection during pregnancy is the focus of serologic
screening during pregnancy.
In Italy, routine serologic screening for CMV infections
among pregnant women has led to an understanding of the
eﬀect of antibodies in preventing and/or possibly reversing
the viral eﬀects of a primary infection during pregnancy
[11, 15–17]. These studies found that the primary eﬀect of
antibodies is most likely on the placenta which, during a
primary CMV infection in the mother, becomes dysfunc-
tional and results in poor oxygenation and nourishment of
the fetus in utero [16]. Thus, many symptoms of congenital
CMV infection that are present at birth may not be due
to any direct eﬀect of the virus on the fetus but rather to
the infection of the placenta which impairs its capacity to
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provide oxygen and nutrition to the developing fetus. Several
lines of evidence suggest this possibility.
First, most manifestations of congenital infection (such
as fetal growth retardation, liver disease, hematopoietic
abnormalities, and splenomegaly) resolve over the early
weeks and months of life, concurrent with adequate oxy-
genation and nutrition. Second, many infants born to
mothers with CMV infection are asymptomatic and develop
normally, despite viremia in utero and postnatally and viral
shedding in urine and saliva for years after birth. Third, CMV
infection is occasionally associated with a “blueberry muﬃn”
syndrome, in which purpura is caused by extramedullary
haematopoiesis that indicates intrauterine hypoxia. Fourth,
hepatomegaly is due to biliary obstruction, secondary to
extramedullary haematopoiesis and erythrocytic congestion
which is also responsible for splenic enlargement in most
symptomatic infants [18]. The increase in placental size
occurs with primary maternal CMV infection because the
placental vasculature enlarges to compensate the fetus [16].
The beneficial eﬀect of antibodies may be mediated through
improved placental function and enhanced supplies of
oxygen, substrates, and nutritional elements to the fetus.
Finally, it has been recently observed that CMV hyperim-
munoglobulin therapy is associated with reduced placental
inflammation and size and fetal ultrasound abnormalities
[11, 15, 16].
3. High-Risk Women
The major risk factor for maternal acquisition of CMV
during pregnancy is frequent and prolonged contact with a
child less than three years of age [20–28]. This occurs among
women with a child in the home or among women employed
in child care centers [24, 29, 30]. CMV seronegative health
care workers, even those caring for hospitalized young
children and infants, are not at an increased risk [31].
Regardless of whether CMV was acquired in utero, via breast
milk, or via contact with other children, unlike older children
and adults, children who are less than age 2 years when they
acquire CMV, shed CMV in urine and saliva for 6 to 42
months with a median of 18 months [32]. In the USA, 60%
of the mothers of children in daycare are CMV seronegative,
and at least 25% of all young children attending large
group child care centers are shedding CMV. Seronegative
mothers with infected children acquire CMV at rates, 10 to
25 times higher than other women in the population [21, 27].
The annual infection rate for seronegative women without
exposure to children is 2% [24].
To estimate the frequency of pregnancy and exposure to
CMV among mothers contemplating a possible additional
pregnancy and with a child less than 2 years of age in
group daycare, we recently performed a prospective study
which included a demographic questionnaire and serologic
and virologic monitoring of mothers and their children in
daycare [33]. Of 60 women, 62% were seronegative and 20%
of seronegative women had a child shedding CMV. Of the 60
women, 23 women or 38% (95% CI = 0.27, 0.51) became
pregnant on average 10 months after study enrollment.
During pregnancy, eight or 35% (95% CI = 0.19, 0.55) of
these pregnant women had a child in daycare who shed CMV.
These results illustrate the potential magnitude of the public
problem associated with exposure to a silent viral infection
during pregnancy. Our data, when extrapolated to the US
population, estimate that every two years between 31,000
and 168,000 susceptible pregnant women will be exposed to
CMV by an infected child.
Another group of high-risk women are those who
are seronegative, young, poor, and predominantly African-
American. Even for this group, contact with a young child is
an independent predictor of delivering a CMV congenitally
infected infant, as is a history of frequent sexual activity
[28]. A recent study monitored CMV seroconversion among
1906 seronegative women attending a fertility clinic [20].
Seroconversion was associated not only with contact with a
child younger than age 3 years but also with seropositivity
of the sex partner. Thus, it is likely that CMV is transmitted
not only via the oral mucosal route, but also via the vaginal
mucosal route. Because CMV is often present in semen, it
may be prudent to include condomuse as part of the hygienic
precautions given to seronegative pregnant women.
4. Accurate Methods for Serologic Diagnosis
The gold standard of serologic diagnosis is maternal sero-
conversion based on the detection of IgG antibodies to
CMV. The IgG assay is nearly 100% sensitive and specific,
readily available, and automated for high volume capacities
[34, 35]. In the absence of universal serial serologic screening
of pregnant women, diagnosis via seroconversion is seldom
achieved since an initial seronegative serum is rarely avail-
able. The detection of IgM antibodies in maternal sera can be
helpful but has problems; although IgM antibodies to CMV
occur in all primary infections, they may also occur after
reactivations or reinfections and the assay has a high false
positive rate. We and others have observed that IgM usually
peaks 3 to 6months after a primary infection butmay remain
present in serum for over 12 months [36]. Hence, finding
IgM to CMV in a single serum of a pregnant woman does
not alone establish a recent primary CMV infection during
pregnancy [37].
Antibody avidity, which is an indirect measure of the
tightness of antibody binding to its target antigen, increases
in the first weeks after a primary infection. Low avidity
IgG antibodies to CMV persist for up to 20 weeks after a
primary CMV infection [10]. These low avidity antibodies
are then replaced by high avidity antibodies (>60% binding
in presence of 5M urea). Currently, the combination of the
presence of anti-CMV IgM antibodies and low avidity anti-
CMV IgG antibodies along with maternal or fetal symptoms
is used for the diagnosis of a primary maternal infection
[38].
5. The Diagnosis of Fetal Infection via
Amniotic Fluid
Amniotic fluid is a helpful adjunct in maternal diagnosis but
cannot replace maternal serologic testing because amniotic
fluid may contain CMV even if the mother was immune to
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Figure 2: A possible algorithm for limited CMV screening during pregnancy.
CMV before conception. The best test for the diagnosis of
intrauterine infection is detection of CMV in the amniotic
fluid by culture and PCR. One of the first studies observed
that amniocentesis correctly identified 12 of 13 (92%)
infants with congenital CMV infection [39]. A subsequent
study observed that amniocentesis was 100% sensitive in
diagnosing congenital CMV infection [40]. A more recent
study observed that viral culture of amniocentesis was 77%
sensitive in detecting congenital CMV infection and the
specificity was 100% [41]. Low sensitivity (false negative
results) in some studies is probably due to infants becoming
infected in utero after the amniotic fluid sampling. False
positive results are rare and when they occur may be due
to maternal contamination of amniotic fluid. For maximal
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accuracy, both viral culture and PCR should be obtained.
A diagnosis of fetal CMV infection alone is insuﬃcient
to predict newborn disease. A large amount of virus as
measured by PCR in the amniotic fluid is most likely related
to gestational age and should not be used as an independent
predictor of a poor fetal outcome [42, 43].
6. Sensitive Fetal and Placental Indicators for
Neonatal Outcomes
Among CMV-infected fetuses, fetal abnormalities or pla-
cental enlargement by ultrasound is predictive of newborn
disease and a poor long-term outcome [11, 15, 44, 45]. In
a prospective study of passive immunization using CMV
hyperimmune globulin, any ultrasound abnormality, exclud-
ing placental thickening, was after multivariate analysis an
independent predictor (P < 0.001) of a poor newborn out-
come [11]. Numerous ultrasound abnormalities have been
described in association with intrauterine CMV infections
and because of normal variations and alternative causes care
must be taken when basing therapeutic decisions solely on
ultrasound abnormalities [11, 44, 45].
One study has evaluated placental thickening in women
with primary CMV infections during pregnancy [15]. In
that study, the placental size of 93 women with a primary
infection and 73 CMV-seropositive pregnant women with-
out primary infection were evaluated. Placental ultrasound
evaluations were performed from 16-to-36-week-gestation.
Women with primary CMV infection and a fetus or newborn
with CMV disease had significantly (P < 0.0001) thicker pla-
centas than women with a primary infection whose fetuses or
newborns were disease free. Women with a primary infection
and whose fetuses were uninfected still had significantly (P <
0.0001) thicker placentas than seropositive controls without
infected fetuses, suggesting the placentas were infected even
though the fetuses were uninfected. Placental thickness
values, predictive of primary maternal infection and/or fetal
disease, were observed at each biweekly measurement from
16-to-36-week-gestation, and cutoﬀ values ranged from 22
to 35mm, with the best sensitivity and specificity at 28 and
32 weeks [14]. Other causes of placental thickening were
excluded in these patients [15].
7. Interventions
Both the CDC and ACOG recommend that pregnant women
be counseled on ways to reduce their risk of CMV acquisition
during pregnancy [46–48]. These simple hygienic precau-
tions are listed in Table 1. Studies demonstrating the eﬃcacy
of hygienic precautions are few but compelling. Studies
completed by our group demonstrated that these hygienic
measures when provided to CMV seronegative pregnant
women with a young child in the home were eﬀective
[22, 23]. In our studies, women were educated about CMV,
and provided written detailed guidelines detailing hygienic
precautions in Table 1, watched a video on how to practice
these precautions, and then were permitted to ask questions
of a research nurse. These precautions were well received by
all of the pregnant women and were easily accomplished.
Table 1: Practices for seronegative pregnant women to reduce risk
of CMV infection.#
(1) Assume that children under age 3 years in your care have
CMV in their urine and saliva
(2) Thoroughly wash hands with soap and warm water after:
diaper changes and handling child’s dirty laundry
feeding or bathing child
wiping child’s runny nose or drool
handling child’s toys, pacifiers, or toothbrushes
(3) Do not:
share cups, plates, utensils, toothbrushes, or food
kiss your child on or near the mouth
share towels or washcloths with your child
sleep in the same bed with your child
#
From [22].
Based on interviews and on a written survey done before
enrollment and at the end of pregnancy, none of 130
seronegative pregnant women complained the precautions
were burdensome or anxiety provoking during pregnancy
[22, 23]. Further, none of the pregnant women declined
serotesting. To date, of 37 pregnant women with a child
shedding CMV, we have observed only one who received
hygienic precautions and seroconverted to CMV during
pregnancy, compared to infection rates of 42% for 64 of 154
nonpregnant women with a child shedding CMV, including
seronegative women who were trying to conceive [22].
This observation has recently been confirmed and expan-
ded in a French study where 5312 pregnant women were
oﬀered CMV serologic screening during pregnancy [12].
Of these women, 97.4% agreed to screening and signed a
consent. If an initial serologic test was negative at 12 weeks
gestation, detailed hygienic information was given orally and
in writing to the woman and her spouse. Wearing protective
gloves was not recommended. For 2595 seronegative women,
the rate of maternal seroconversion during the first 12 weeks
of gestation was compared to the rate between weeks 12 and
36. Prior to patient education and the receipt of hygienic
precautions at 12 weeks, the maternal seroconversion rate
was 0.42%, compared with a rate of 0.19% for women
from week 12 to 36 of the gestation. When adjusted for
the number of woman-weeks observed, the rate prior to 12
weeks gestation was 0.035% per woman-week compared to
a rate of 0.008% per woman-week after intervention (P =
0.005). Maternal primary infections and seroconversions
were distributed evenly throughout gestation [12].
These studies provide compelling data on the simplicity
and eﬀectiveness of hygienic intervention to prevent CMV
infection of high-risk pregnant women who are tested for
CMV during pregnancy. Although seronegative health care
workers do not have an increased risk, pregnant child care
employees are at a significant risk for CMV acquisition. In
2008, the CDC website recommended that pregnant child
care employees be informed they could assess, their risk
by serologic testing and if seronegative, avoid if possible
6 Infectious Diseases in Obstetrics and Gynecology
caring for children less than 2 years age for the duration of
pregnancy.
Serial serologic screening would identify pregnant
women with a primary CMV infection prior to fetal
infection. For these women, prompt passive immunization
may prevent fetal infection. Prevention of fetal infection
with a high titer CMV immunoglobulin (HIG) preparation
was reported in 2005 [11]. In a prospective Phase I-II trial,
181 pregnant women with a primary CMV infection were
identified. Most women were asymptomatic and identified
by serologic screening. For women with a primary infection
at <21 weeks’ gestation or for those who refused amniocen-
tesis, HIG (100U/kg of maternal weight) was administered
monthly until delivery. Of 126 women (mean gestational age
at infection 14.3. + 7 weeks) who did not receive HIG, 56%
delivered infected infants, compared with 16% of 37 women
(mean gestational age at infection, 13.2 + 5.5 weeks) who
received prophylactic HIG (P < 0.001). In this study, it is
likely that the true eﬃcacy of HIGmay have been greater than
actually observed because a few of the fetuses may have been
infected in utero before HIG was administered. Although
this was not a randomized controlled trial, the observations
were consistent with the observations for natural infection.
That is, women who have prepregnancy antibodies to CMV
acquired by a natural infection have a markedly reduced rate
of mother-to-fetus transmission of CMV.
In the same study, passive immunization was also
evaluated in women with proven fetal infection [11]. Forty-
five women had a primary infection more than 6 weeks
before enrollment and underwent amniocentesis to detect
CMV DNA or virus in amniotic fluid. Thirty-one of these
women, whose fetuses were infected, received HIG. Fourteen
women with infected fetuses declined HIG and half of them
delivered infants with a symptomatic CMV infection. In
contrast, only 1 of the 31 women who received HIG delivered
a diseased infant at birth (adjusted odds ratio, 0.02; P <
0.001). In particular, 15 treated women had fetuses with
ultrasound abnormalities consistent with an intrauterine
CMV infection. Fourteen infants of these 15 fetuses were
healthy despite the prenatal ultrasound signs of involvement.
Administration of HIG to the mother and fetal ultrasound
abnormalities before treatment were independent predictors
of fetal outcome (P < 0.001).
After primary infection, for women with or without
infected fetuses or newborns, treatment with HIG was
associated with significant (P < 0.001) reductions in
placental thickness, placental inflammation, and placental
viral load for seroconversion for gestational weeks 12 to
36 [15, 16]. A limitation of HIG administration is that
it does not appear to aﬀect hearing deficit [17]. This is
anticipated since the incidence of hearing deficit among
congenitally infected infants is independent of preconception
high titer high avidity maternal antibodies and may progress
postnatally in spite of high titer neonatal antibodies [13].
Regarding the safety of HIG, no toxicity has been
observed and immunoglobulins have been used safely
in pregnancy since the 1950s [47–51]. Intravenous
immunoglobulins are the most purified among the
blood derivatives, including albumin, and are pasteurized.
Intravenous immunoglobulins are used each year to safely
treat many tens of thousands of patients such as transplant
patients and those with Kawasaki’s disease, immune
deficiencies, thrombocytopenia, and so forth. For a woman
with a primary CMV infection during pregnancy, legitimate
safety concerns have to be weighed against the risk of an
aﬀected infant or fetus.
8. Cost Benefit and Feasibility of
Maternal Screening
Given that nine countries routinely screen half or more of
all pregnant women serially during pregnancy for serocon-
version to CMV, it appears that the logistical and economic
challenges of implementing screening for CMV on a large
scale have been overcome in these countries. In the USA
pregnant women are now routinely screened for rubella,
syphilis, hepatitis, and HIV. Thus, adding CMV to ongoing
serologic testing is feasible.
The cost/eﬀectiveness of both passive and active immu-
nization against CMV have been formally estimated in 4
studies and was cost-eﬀective in each study [4, 52–54]. Two
cost/benefit studies have addressed universal screening and
passive immunization [53, 54]. One recent study found that
universal serologic screening (as compared to screening,
only high-risk women or those with abnormal ultrasound
findings) was the preferred and most cost-eﬀective approach
[54]. This conclusion assumed that serologic testing occurred
one time at 20 weeks gestation and that passive immu-
nization as therapy (as opposed to prevention) would be
at least 47% eﬀective. Another recent study of passive
immunization during pregnancy also used QUALYS and
decision analysis (CEA ) [53]. This model also incorporated
universal maternal serial serological screening in pregnancy.
In both the treatment and prophylaxis protocols as described
by Nigro et al. [11], universal maternal serologic screening
for CMV status and seroconversion in pregnancy followed
by maternal HIG was cost-eﬀective in the reduction of
CMV sequelae in newborns. The model demonstrated both
cost savings and a reduction in CMV disease cases. The
optimal model demonstrated a reduction in congenital CMV
cases with disease from 7.2/10,000 to 3.5/10,000 requiring
treatment of 2.3 pregnancies per case prevented. This model
applied over the majority of the US population, remaining
cost eﬀective for maternal seroconversion rates in pregnancy
>1%, termination rates <10%, and maternal prepregnancy
immunity rates of 50–80%.
9. Comment
Universal serologic screening whether by an initial blood test
or by serial testing during pregnancy for a primary CMV
infection is controversial [55, 56]. In the USA, all women
are screened via ultrasound at around 20 weeks gestation.
When CMV-associated fetal abnormalities are detected and
an intrauterine CMV infection confirmed by amniocentesis,
data from the new National CMV Registry for Pregnant
Women (CMVregistry.org) indicate oﬀ-label HIG is often
used. Of the first 48 women enrolled in the registry, 23 had
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Table 2: Estimated annual impact in the USA of group child care on the rate of congenital CMV infection among multiparous Caucasians
compared to multiparous non-Caucasians without group child care.
Caucasian Non-Caucasian
No. live births/year 3,000,000∗ 1,000,000∗
No. of seronegative mothers at conception 1,800,000 (60%) 200,000 (20%)&
No. with previous child at home 900,000 (50%) Unknown
No. with previous child <3 years at conception 675,000 (75%) Unknown
No. with child in day care 506,250 (75%) Unknown
No. with shedding child 126,563 (25%) Unknown
No. becoming infected during pregnancy 53,156 (42%) 15,600 (7.8%)&
No. of infants infected in utero (50%) 26,578 7,800
No. of infants with severe sequella+ (28%) 7,442 2,184
∗
US Bureau of Vital Statistics.
+Death, I.Q. < 70, or deafness.
&Based on data from [3, 13, 14].
positive amniotic fluid and 18 (78%) were treated oﬀ-label
with HIG (Cytogam). While apparently safe, this approach
is far from ideal. Treatment is given only to fetuses of
mothers infected in early gestation and who have the poorest
prognosis.
Although some have argued for not using HIG without
a randomized clinical eﬃcacy trial, for several reasons such
a trial is very unlikely and no such clinical trial is ongoing
or contemplated [56, 57]. Obstacles to a therapeutic trial
include: subject acceptance of placebo when the study drug
appears safe and is readily available oﬀ label, the need to
serologically test over 100,000 pregnant women to identify
a few hundred with fetal infection, the high costs associated
with a large multicenter trial and a lack of interest by
government, and industry in financing such a trial.
A better clinical trial design is one that prevents fetal
infection with HIG following a primary maternal infection.
Two such trials are ongoing in Europe where serologic
screening identifies CMV-infected women during pregnancy.
The interim results of one such trial are encouraging [58]. To
perform these studies in the USA requires annual serologic
screening of at least 20,000 pregnant women and to date no
such studies have been funded in the USA.
Postponing CMV testing of pregnant women until the
problem is solved by an active vaccine is unrealistic. Older
active CMV vaccines have had limited success and there are
no current clinical trials of new vaccines [59, 60]. Thus the
licensing of an active CMV vaccine is probably at least a
decade away.
Hygienic intervention for high-risk women is appropri-
ate now. At least one-third of the pregnant women in the
US are high risk (Table 2); that is, they have daily household
or occupational contact with children less than 3 years
old. Oﬀering an initial blood test for CMV IgG antibodies
in pregnancy, educating them about CMV, and providing
simple hygienic precautions could be routine. Testing of their
living children for CMV excretion is not useful since they
may not be shedding CMV initially but start shedding at
anytime during their mother’s pregnancy [22].
Whether to continue serial testing for seroconversion
during pregnancy could initially be a decision for each
woman and her obstetrician. In other countries the main
rationale for universal serial screening was apparently to
allow for an elective termination of pregnancy. In Israel
approximately half of women who seroconvert to CMV
electively terminate, although this rate is much lower in other
countries [61, 62]. Figure 2 shows one possible algorithm for
limited maternal screening.
An alternative to serologic screening is to provide all
high-risk pregnant women the hygienic interventions. In
the reported studies, however, women knew their serologic
status, so it is unclear if a pregnant woman’s perception
of her risk (susceptible) would aﬀect eﬃcacy. Hygienic
precautions do not work in nonpregnant women, suggesting
seronegative pregnant women perceive a high risk and are
more motivated to comply [22, 23]. It is very likely that most
high-risk women would want to assess their risk by knowing
their serologic status given that serologic testing is readily
available.
Even limited serologic screening as suggested in Figure 2
has potential adverse eﬀects such as false positive or negative
IgG results which may lead to apparent seroconversion and
thus increased costs associated with additional serologic
testing or unnecessary imaging and amniocentesis. The
negative impact of these potential problems has not been
reported, although this could be studied in countries that
now use routine serologic screening.
Regardless of the strategy used, no serologic testing, only
hygienic precautions, one time testing, or serial serologic
testing through out the first two trimesters of pregnancy,
education of pregnant women about CMV is necessary. With
a rare exception, the reaction of women and especially those
who acquire a CMV infection during pregnancy is that they
wish they had known about CMV and could have taken some
measures to avoid infection.
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